loading...

Injection Treatment Acceptance Questionnaire (I-TAQ)

Sanofi Aventis; Regeneron Pharmaceuticals Inc

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

  • Published in 2015
Authors

Sanofi Aventis; Regeneron Pharmaceuticals Inc

Copyright
I-TAQ © Version 1, 13 March 2015 Sanofi and Regeneron Pharmaceuticals Inc. All Rights Reserved.
Objective
To assess treatment acceptance with a subcutaneous injection therapy for an asymptomatic condition
Therapeutic area
  • Generic
Therapeutic indication

All

Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Tatlock S, Grant L, Spertus JA, Khan I, Arbuckle R, Manvelian G, Sanchez RJ. Development and Content Validity Testing of a Patient-Reported Treatment Acceptance Measure for Use in Patients Receiving Treatment via Subcutaneous Injection. Value Health. 2015 Dec;18(8):1000-7 (Full text article)

Tatlock S, Arbuckle R, Sanchez R, Grant L, Khan I, Manvelian G, Spertus JA. Psychometric Evaluation of a Treatment Acceptance Measure for Use in Patients Receiving Treatment via Subcutaneous Injection. Value Health. 2017 Mar;20(3):430-440 (Full text article)


Contact and conditions of use

Authors

Sanofi Aventis; Regeneron Pharmaceuticals Inc

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

Non-Commercial Users

If you do not receive specific funding for your study, you may download the questionnaire directly:

  1. Log in or Register for free
  2. Click the 'Online distribution' tab in the left menu bar and follow the instructions

Tutorials are available on our FAQs.

Commercial Users

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. In order to accelerate the process, you may attach the User Agreement (even if not finalized) to your online request. Click the link below for the user agreement template.
  4. Our PROVIDE team will get back to you with the needed information in a timely manner

Access fees

ROYALTY FEES* Commercial users Cost per study 1 000 €
Cost per language 1 000 €
Funded academic research Cost per study Free
Cost per language Free
Not funded academic users Cost per study Free
Cost per language Free
DISTRIBUTION FEES* Commercial users Cost per study 700 €
Cost per language 300 €
Funded academic research Cost per study 300 €
Cost per language 50 €
Not funded academic users Cost per study Free
Cost per language Free

* Excluding VAT
Commercial users: Industry, CRO, any for-profit companies
Funded Academic research: Projects receiving funding from commerce, government, EU or registered charity. Funded academic research– sponsored by industry fits the “commercial users” category.
Not funded academic users, individual medical practice: Projects are not explicitly funded, but funding comes from overall departmental funds or from the University or individual funds

Conditions to translate

Please refer to the "Languages" tab

Conditions to implement in electronic applications

Exclusive licensor for e-versions of the questionnaireMapi Research Trust

Academic and Commercial Users
  • Shall follow the “Conditions of use”  mentioned above
  • In addition, in case the electronic version of the questionnaire is developed by a third party (IT Company, e-PRO vendor…), User shall check with Mapi Research Trust that this third party has signed the necessary License Agreement with Mapi Research Trust before developing the electronic version of the Questionnaire.

Information Technology (IT) Companies (incl. ePRO vendors)
  • In case of a one-shot development and commercial use of an electronic version of the questionnaire by the IT Company, the IT Company shall:
    • Sign a “Specific-Study License Agreement with IT Company” with Mapi Research Trust
      • authorizing the electronic implementation of the questionnaire for the specific study only
      • shall not permit the IT Company to promote the electronic version of the questionnaire or its use for another study or another client
        The implementation in this specific context is free of charge.
  • In case of an IT Company who wishes to develop an electronic version of the questionnaire and would like to obtain a non-exclusive license to market and promote their devices / tablets / smartphones / e-applications using the questionnaire, the IT Company shall:
    • Sign a “General License Agreement with IT Company” with Mapi Research Trust
      • authorizing the electronic implementation of the questionnaire on multiple devices for multiple studies and clients
      • permitting the IT Company to promote the electronic versions of the questionnaire by any marketing means (including, but not limited to, IT Company’s  promotional documents / websites / press release / communication during conferences / webinars)
    • Pay one-shot development fee of 2,000 Euros to Mapi Research Trust

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Languages

Original language(s)

  • English for the USA

Translations

The listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study. This list is subject to constant changes, therefore please check the status of translations with Mapi Research Trust / the developers / copyright holders / distributors.

I-TAQ_AU1.0

Afrikaans for South Africa
Arabic for Israel
Arabic for Kuwait
Arabic for Lebanon
Arabic for Saudi Arabia
Arabic for the United Arab Emirates
Catalan for Spain
Chinese for China
Chinese for Hong Kong
Chinese for Taiwan
Danish for Denmark
Dutch for Belgium (Flemish)
Dutch for the Netherlands
English for Canada
English for the UK
Finnish for Finland
French for Belgium
French for Canada
French for France
French for Switzerland
German for Germany
German for Switzerland
Greek for Greece
Hebrew for Israel
Hungarian for Hungary
Italian for Italy
Italian for Switzerland
Korean for Korea
Norwegian for Norway
Portuguese for Brazil
Russian for Russia
Spanish for Spain
Spanish for the USA
Swedish for Sweden
Turkish for Turkey
Ukrainian for Russia

The author has selected Mapi as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi

More information on translations

For information on, or permission to use the translations, please contact Mapi Research Trust

Online distribution

My study is not funded

  • I am a non-commercial user
  • I do not receive specific funding for my study
  • I intend to use the questionnaire in individual clinical practice or research study
Login SIGN up free

My study is funded

If your study is funded, or if you haven't found your translation in the Languages menu, please submit your request online.

Our team will get back to you as soon as possible.

Member Access

Subscribe to PROQOLID to access to full informations

And get access to advanced descriptions of Clinical Outcome Assessments (COAs)!

A question? Contact us